AbCellera Biologics Inc. (ABCL)
Health Care ยท Pharmaceutical Preparations
AbCellera Biologics Inc. (ABCL) is listed on Nasdaq, where its shares have traded since December 11, 2020. SentiSense covers AbCellera Biologics Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations. Carl Hansen is its chief executive officer. The company reports 562 employees, and its corporate website is www.abcellera.com.
About AbCellera Biologics Inc.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 148 institutions reported holding ABCL, with 116.0 million shares worth $907.9 million in aggregate. The largest reported holders were Baker Bros. Advisors, Capital Group and Two Sigma Investments. Of the 5 largest reported holders, 3 added shares and 2 reduced their positions during the quarter.
More on ABCL
- ABCL sentiment: whether news and social coverage of AbCellera Biologics Inc. leans bullish or bearish, and the stories driving it.
- ABCL ownership: all 148 reporting institutions, plus insider and congressional trades.
- ABCL financials: revenue, net income, operating margin and free cash flow by quarter and year.
SentiSense also tracks daily options readings for AbCellera Biologics Inc.: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does AbCellera Biologics Inc. do?
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need.
What sector is ABCL in?
SentiSense classifies AbCellera Biologics Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations.
Where does ABCL stock trade?
AbCellera Biologics Inc. (ABCL) is listed on Nasdaq, where its shares have traded since December 11, 2020.
Who is the CEO of AbCellera Biologics Inc.?
Carl Hansen is the chief executive officer of AbCellera Biologics Inc..